EP Patent

EP2611436A1 — Combination of hdac inhibitors with thrombocytopenia drugs

Assigned to Novartis AG · Expires 2013-07-10 · 13y expired

What this patent protects

The invention relates to a combination which comprises : (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases. The invention also relates to pharmaceu…

USPTO Abstract

The invention relates to a combination which comprises : (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases. The invention also relates to pharmaceutical compositions or products comprising such a combination, or a method using such a combination.

Drugs covered by this patent

Patent Metadata

Patent number
EP2611436A1
Jurisdiction
EP
Classification
—
Expires
2013-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.